相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。2013 Alzheimer's disease facts and figures Alzheimer's Association
William Thies et al.
ALZHEIMERS & DEMENTIA (2013)
Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease
Aaron H. Burstein et al.
CLINICAL NEUROPHARMACOLOGY (2013)
Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease: A Phase I, Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study
Jaren W. Landen et al.
CLINICAL NEUROPHARMACOLOGY (2013)
Intravenous immunoglobulin and Alzheimer's disease: what now?
David A. Loeffler
JOURNAL OF NEUROINFLAMMATION (2013)
Immunogenicity, Efficacy, Safety, and Mechanism of Action of Epitope Vaccine (Lu AF20513) for Alzheimer's Disease: Prelude to a Clinical Trial
Hayk Davtyan et al.
JOURNAL OF NEUROSCIENCE (2013)
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial
Richard Dodel et al.
LANCET NEUROLOGY (2013)
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
Victor L. Villemagne et al.
LANCET NEUROLOGY (2013)
Immunotherapy for Alzheimer's disease: hoops and hurdles
Cynthia A. Lemere
MOLECULAR NEURODEGENERATION (2013)
Active vaccination with ankyrin G reduces β-amyloid pathology in APP transgenic mice
A. C. Santuccione et al.
MOLECULAR PSYCHIATRY (2013)
Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model
Jose Morales-Corraliza et al.
NEUROBIOLOGY OF AGING (2013)
Development of a New DNA Vaccine for Alzheimer Disease Targeting a Wide Range of Aβ Species and Amyloidogenic Peptides
Yoh Matsumoto et al.
PLOS ONE (2013)
Safety and biomarker effects of Solanezumab in patients with Alzheimer's disease
Martin Farlow et al.
ALZHEIMERS & DEMENTIA (2012)
Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab
Susanne Ostrowitzki et al.
ARCHIVES OF NEUROLOGY (2012)
Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease
Kaj Blennow et al.
ARCHIVES OF NEUROLOGY (2012)
Gantenerumab for the treatment of Alzheimer's disease
Julien Delrieu et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Solanezumab for the treatment of mild-to-moderate Alzheimer's disease
Bruno P. Imbimbo et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2012)
Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies
Francesco Panza et al.
IMMUNOTHERAPY (2012)
Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis
Jungsu Kim et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Intranasal inoculation with an adenovirus vaccine encoding ten repeats of Aβ3-10 reduces AD-like pathology and cognitive impairment in Tg-APPswe/PSEN1dE9 mice
Yu Li et al.
JOURNAL OF NEUROIMMUNOLOGY (2012)
An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique Aβ Binding Properties Promotes Neuroprotection and Glial Engulfment of Aβ
Oskar Adolfsson et al.
JOURNAL OF NEUROSCIENCE (2012)
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
Bengt Winblad et al.
LANCET NEUROLOGY (2012)
Genentech's Alzheimer's antibody trial to study disease prevention
Ken Garber
NATURE BIOTECHNOLOGY (2012)
Passive Immunization against Pyroglutamate-3 Amyloid-β Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study
Jeffrey L. Frost et al.
NEURODEGENERATIVE DISEASES (2012)
A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
Ronald B. DeMattos et al.
NEURON (2012)
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
Randall J. Bateman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Stopping Alzheimer's Before It Starts
Greg Miller
SCIENCE (2012)
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup
Reisa A. Sperling et al.
ALZHEIMERS & DEMENTIA (2011)
Anti-β-Amyloid Immunotherapy for Alzheimer's Disease: Focus on Bapineuzumab
Francesco Panza et al.
CURRENT ALZHEIMER RESEARCH (2011)
Antibody-based therapy in Alzheimer's disease
Refik Pul et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
The Second-Generation Active Aβ Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects
Christoph Wiessner et al.
JOURNAL OF NEUROSCIENCE (2011)
Alzheimer's disease: clinical trials and drug development (vol 9, pg 702, 2010)
F. Mangialasche et al.
LANCET NEUROLOGY (2011)
The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia
Jessica M. Mc Donald et al.
BRAIN (2010)
Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid beta After a Single Administration of an Amyloid beta Monoclonal Antibody in Subjects With Alzheimer Disease
Eric R. Siemers et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Revising the definition of Alzheimer's disease: a new lexicon
Bruno Dubois et al.
LANCET NEUROLOGY (2010)
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Juha O. Rinne et al.
LANCET NEUROLOGY (2010)
Alzheimer's disease: clinical trials and drug development
Francesca Mangialasche et al.
LANCET NEUROLOGY (2010)
Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders
Bruno Vellas et al.
CURRENT ALZHEIMER RESEARCH (2009)
Disease-Modifying Approach to the Treatment of Alzheimer's Disease From alpha-Secretase Activators to gamma-Secretase Inhibitors and Modulators
Francesco Panza et al.
DRUGS & AGING (2009)
Vaccination with Aβ-Displaying Virus-Like Particles Reduces Soluble and Insoluble Cerebral Aβ and Lowers Plaque Burden in APP Transgenic Mice
Patricia Bach et al.
JOURNAL OF IMMUNOLOGY (2009)
DEVELOPMENT OF AFFITOPE VACCINES FOR ALZHEIMER'S DISEASE (AD) - FROM CONCEPT TO CLINICAL TESTING
A. Schneeberger et al.
JOURNAL OF NUTRITION HEALTH & AGING (2009)
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
S. Salloway et al.
NEUROLOGY (2009)
Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques
Robert M. Koffie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
DNA epitope vaccine containing complement component C3d enhances anti-amyloid-β antibody production and polarizes the immune response towards a Th2 phenotype
Nina Movsesyan et al.
JOURNAL OF NEUROIMMUNOLOGY (2008)
Long-term effects of Aβ42 immunisation in Alzheimer's disease:: follow-up of a randomised, placebo-controlled phase I trial
Clive Holmes et al.
LANCET (2008)
Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory
Ganesh M. Shankar et al.
NATURE MEDICINE (2008)
Antibody capture of soluble A beta does not reduce cortical A beta amyloidosis in the PDAPP mouse
Peter Seubert et al.
NEURODEGENERATIVE DISEASES (2008)
Reducing AD-Like Pathology in 3xTg-AD Mouse Model by DNA Epitope Vaccine - A Novel Immunotherapeutic Strategy
Nina Movsesyan et al.
PLOS ONE (2008)
Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Aβ species in amyloid precursor protein transgenic mice
Irina Petrushina et al.
JOURNAL OF NEUROSCIENCE (2007)
Research criteria for the diagnosis of Alzheimers disease: revising the NINCDS-ADRDA criteria
Bruno Dubois et al.
LANCET NEUROLOGY (2007)
Absence of β-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia
Stephanie Bombois et al.
ARCHIVES OF NEUROLOGY (2007)
Monoclonal antibodies that target pathological assemblies of A beta
Mary P. Lambert et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Alzheimer's disease and the aging brain
Robert D. Terry
JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY (2006)
Nonviral Aβ DNA vaccine therapy against Alzheimer's disease:: Long-term effects and safety
Yoshio Okura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
A specific amyloid-β protein assembly in the brain impairs memory
S Lesné et al.
NATURE (2006)
Targeting amyloid-β peptide (Aβ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Aβ precursor protein (APP) transgenic mice
EB Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
S Gilman et al.
NEUROLOGY (2005)
HSV amplicon-mediated Aβ vaccination in Tg2576 mice:: differential antigen-specific immune responses
WJ Bowers et al.
NEUROBIOLOGY OF AGING (2005)
Mechanisms of A beta Plaque Clearance following Passive A beta Immunization
Dave Morgan
NEURODEGENERATIVE DISEASES (2005)
Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from β-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide
MG Agadjanyan et al.
JOURNAL OF IMMUNOLOGY (2005)
Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD
AJ Bayer et al.
NEUROLOGY (2005)
Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease
E Masliah et al.
NEUROLOGY (2005)
Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome
S Oddo et al.
NEURON (2004)
Gene vaccination to bias the immune response to amyloid-β peptide as therapy for Alzheimer disease
BX Qu et al.
ARCHIVES OF NEUROLOGY (2004)
Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease
I Ferrer et al.
BRAIN PATHOLOGY (2004)
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
JM Orgogozo et al.
NEUROLOGY (2003)
Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease
C Hock et al.
NEURON (2003)
Reduction of β-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization
D Frenkel et al.
VACCINE (2003)
Neuropathology of cognitively normal elderly
DS Knopman et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2003)
Interactions of amyloidogenic proteins
BI Giasson et al.
NEUROMOLECULAR MEDICINE (2003)
Amyloid-β immunotherapy for Alzheimer's disease:: the end of the beginning
D Schenk
NATURE REVIEWS NEUROSCIENCE (2002)
The cell biology of Alzheimer's disease: uncovering the secrets of secretases
J Walter et al.
CURRENT OPINION IN NEUROBIOLOGY (2001)
Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ42 fibrils
J Götz et al.
SCIENCE (2001)
Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice
EM Sigurdsson et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
F Bard et al.
NATURE MEDICINE (2000)
分享论文
